Bold New Bioengineering Methods and Approaches for Heart, Lung, Blood and Sleep Disorders and Diseases (R21)

RFA-HL-17-015
Bold New Bioengineering Methods and Approaches for Heart, Lung, Blood and Sleep Disorders and Diseases (R21)
Department of Health and Human Services
National Institutes of Healthnew lungs

Purpose

The purpose of this funding opportunity announcement (FOA) is to seek innovative, high-risk bioengineering research for which preliminary results have not yet been obtained, explore new approaches or concepts that are important to a substantive heart, lung, blood or sleep disorder or disease, support the translation of research into practice, technologies, or commercial products, and to develop trans-disciplinary projects upon which significant future research may be built.  This  program will allow investigators to enter new fields and apply cutting-edge approaches to improve the Nation’s health through bioengineering research.  In particular, ground-breaking studies aimed towards the development of novel agents, materials or coatings related to medical devices and engineered tissues would be uniquely fostered by this FOA.

Background

Originally conceptualized by the NIH Bioengineering Consortium in 2003, NHLBI Exploratory Bioengineering Research Grants (EBRGs) were submitted under PA-12-284 (reissued as PA-16-040, which is administered by NIBIB).  NHLBI examined its EBRG R21 portfolio and found this funding mechanism as a useful and cost-effective way for established investigators to open new areas of research. Our data suggests that low-cost, short term projects may incentivize research teams, especially those not captured by the traditional R01 mechanism.

Why Bioengineering? The NHLBI bioengineering community has transformed medicine by creating the artificial heart, pacemakers and Implantable Cardioverter Defibrillators, Ventricular Assist Devices, stents, human tissue chip devices and cell/gene/combination product therapies. These examples demonstrate that bioengineering is a synergistic approach that crosses not only all technology-related areas of NHLBI, but also all of our Disease-specific domains. Further, bioengineering is unique because unlike most scientific focuses, such as heart disease, it demands collaboration across disciplines, which looks to be necessary for advancement of needed technologies. Our ability to achieve alternative and more effective therapies is an urgent need for NHLBI. It is envisioned that this targeted RFA will serve as an opportunity to address scientific gaps and to programmatically balance bioengineering projects across the NHLBI. We are seeking only the most unique, highly innovative and groundbreaking approaches with potential for significant impact on reducing the burden of disease. Applicants are advised to query NIH RePORTER to make sure their approach or idea has not been funded before.

The use of the R21 mechanism is intended to support short-term exploratory research projects. Long-term projects, or projects designed to increase knowledge in a well-established area, will not be considered for R21 awards. Additionally, R21 applications may involve considerable risk, so they should clearly explain the significance of the proposed work and why the potential impact outweighs these risks

General Information

Document Type: Grants Notice
Funding Opportunity Number: RFA-HL-17-015
Funding Opportunity Title: Bold New Bioengineering Methods and Approaches for Heart, Lung, Blood and Sleep Disorders and Diseases (R21)
Opportunity Category: Discretionary
Opportunity Category Explanation:
Funding Instrument Type: Grant
Category of Funding Activity: Health
Category Explanation:
Expected Number of Awards:
CFDA Number(s): 93.233 — National Center on Sleep Disorders Research
93.837 — Cardiovascular Diseases Research
93.838 — Lung Diseases Research
93.839 — Blood Diseases and Resources Research
93.840 — Translation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders
Cost Sharing or Matching Requirement: No
Posted Date: Jun 13, 2016
Last Updated Date: Jun 13, 2016
Original Closing Date for Applications: May 10, 2019  
Current Closing Date for Applications: May 10, 2019  
Archive Date: Jun 10, 2019
Estimated Total Program Funding: $1,350,000
Award Ceiling: $150,000

Eligibility

Eligible Applicants:
For profit organizations other than small businesses
Special district governments
County governments
City or township governments
State governments
Public and State controlled institutions of higher education
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Public housing authorities/Indian housing authorities
Small businesses
Native American tribal organizations (other than Federally recognized tribal governments)
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Independent school districts
Others (see text field entitled “Additional Information on Eligibility” for clarification)
Native American tribal governments (Federally recognized)
Private institutions of higher education
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.

Additional Information

Agency Name: National Institutes of Health
Description: The purpose of this Funding Opportunity Announcement (FOA) is to encourage basic, translational, and clinical proof-of-concept research projects that are needed for the advancement of bioengineering approaches for heart, lung, blood and sleep diseases.
Link to Additional Information: http://grants.nih.gov/grants/guide/rfa-files/RFA-HL-17-015.html
Contact Information: If you have difficulty accessing the full announcement electronically, please contact:

NIH OER Webmaster FBOWebmaster@OD.NIH.GOV
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster

Advertisements

NHLBI TOPMed: Omics Phenotypes of Heart, Lung, and Blood Disorders (X01)

PAR-16-021
NHLBI TOPMed: Omics Phenotypes of Heart, Lung, and Blood Disorders (X01)
Department of Health and Human Services
National Institutes of Health

fig1

Types of Research Projects

This FOA is intended to support studies of common, complex disorders that significantly affect heart, lung, and blood (HLB) systems. Applicants should contact NHLBI staff prior to preparing an application to discuss the purpose and scope of their applications and to obtain updates regarding the technical requirements and analytical capabilities of the program. Applicants may, in a single application, apply to use one or more of the five omics assays listed above to accomplish a cohesive research goal. In accordance with the NIH Genomic Data Sharing Policy, all omics and related phenotypic data are expected to be shared with the broader research community through a public database such as dbGaP, consistent with achieving the goals of the program. Since dbGaP is built primarily for genotypic data, NIH may work with applicants to determine the details of how other omics datasets should be stored in dbGaP and/or other related databases supported by NIH.  Successful applicants will be invited and expected to join NHLBI’s TOPMed consortium and participate in its advisory and collaborative discussions.

Whole Genome Sequencing (WGS):

In general, WGS applications may aim to discover influential genetic variants underlying HLB disorders using various experimental designs (e.g., family-based, case-control, or a mix of both); if the same subjects for WGS also have other omics data, applicants may use integrative omics approaches to identify gene-regulatory networks or other functions of genomic variants. Currently, this FOA offers a standard protocol for sequencing whole human genome from high quality genomic DNA (preferably not whole genome amplified DNA). An NHLBI-designated informatics center will perform basic data processing, including variant-calling (e.g., SNPs, SNPs, and copy number variants (CNVs)) as well as submission of sequencing data to dbGaP. Applicants may also perform their own variant-calls if the standard variant-call is not appropriate to their research aims. For applicants with limited experience in or resources for handling genomic data, the sequencing centers and/or the NHLBI’s informatics center will be able to provide some genomic data analysis capacity, and those applicants will need to work with the centers to provide clinical measurements and other data required for phenotype-genotype analyses. For applications using large numbers of samples, applicants are encouraged, when possible, to divide sample collections into smaller, phased projects within a single application, starting with the minimum number of subjects needed for initial discovery. After approval to access the sequencing capacity, X01 applicants will work with NHLBI, NHGRI, and the sequencing centers to determine the timing and number of DNA samples to be sequenced.

Other Omics Assays:

Omics data other than whole genome sequence (e.g., RNA, methylation, metabolites, and proteins) may be highly useful for studies of gene-gene and gene-environment interactions. Such studies benefit from the availability of datasets which contain multi-omics data and WGS data that have all been measured on the same subjects and which also include rich clinical and environmental measurements. Because the sample preparation protocols for other omics measures (RNA-seq, DNA methylation, metabolite-profiling, and protein profiling) are expected to be more complex than that for WGS, applicants are encouraged to consult the FAQ page and contact NHLBI staff for updated protocol specifications. Large scale applications are permitted, but applicants proposing large sample sizes are encouraged to organize their study as a series of phased projects involving a smaller number of samples in each phase, if possible.

General Information

Document Type: Grants Notice
Funding Opportunity Number: PAR-16-021
Funding Opportunity Title: NHLBI TOPMed: Omics Phenotypes of Heart, Lung, and Blood Disorders (X01)
Opportunity Category: Discretionary
Funding Instrument Type: Grant
Category of Funding Activity: Health
Category Explanation:
Expected Number of Awards: 10
CFDA Number(s): 93.233 — National Center on Sleep Disorders Research
93.837 — Cardiovascular Diseases Research
93.838 — Lung Diseases Research
93.839 — Blood Diseases and Resources Research
Cost Sharing or Matching Requirement: No
Posted Date: Oct 29, 2015
Creation Date: Oct 30, 2015
Original Closing Date for Applications: Jan 18, 2019  
Current Closing Date for Applications: Jan 18, 2019  
Archive Date: Feb 18, 2019
Estimated Total Program Funding:
Award Ceiling:
Award Floor:

Eligibility

Eligible Applicants:
Native American tribal governments (Federally recognized)
Others (see text field entitled “Additional Information on Eligibility” for clarification)
Native American tribal organizations (other than Federally recognized tribal governments)
Independent school districts
State governments
Private institutions of higher education
County governments
Public housing authorities/Indian housing authorities
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Small businesses
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Special district governments
Public and State controlled institutions of higher education
City or township governments
For profit organizations other than small businesses
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

Additional Information

Agency Name: National Institutes of Health
Description: This Funding Opportunity Announcement (FOA) invites applications to use NIH-funded omics capacity to carry out studies of the genetic basis and/or omics signatures of common, complex heart, lung, and blood disorders. Successful applicants will provide biospecimens for whole genome sequencing or other omics assays. No funding will be provided under this FOA. The omics data and related phenotypic data will be deposited in a public database such as dbGaP.
Link to Additional Information: http://grants.nih.gov/grants/guide/pa-files/PAR-16-021.html
Contact Information: If you have difficulty accessing the full announcement electronically, please contact:

NIH OER Webmaster FBOWebmaster@OD.NIH.GOV
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster